// App-Quantinova.ai

2551 : Phase I/II dose-escalation and expansion study of afuresertib + carboplatin and paclitaxel in recurrent ovarian cancer.

Researchers

Presenter

  • Sarah Patricia Blagden

Principal Investigators

  • Hani Gabra

  • Anne L. Hamilton

  • Shirley S. Wong

  • Agnieszka Michael

  • Linda R. Mileshkin

  • Marcia Hall

  • Jeffrey Goh

  • Alla Sergeevua Lisyanskaya

  • Michelle DeSilvio

  • Dany Habr

  • Shelby Gainer

  • Prashanth Gopalakrishna

  • Tarek Meniawy

Medical Centers

  • OCA Research Centre, Imperial College London, London, United Kingdom

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Western Hospital, Brunswick, Australia

  • University of Surrey, Guildford, United Kingdom

  • Mount Vernon Cancer Centre, Middlesex, United Kingdom

  • Royal Brisbane and Women's Hospital, Herston, Australia

  • St Petersburg City Oncology Hospital, St Petersburg, Russia

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis AG, Basel, Switzerland

  • Linear Clinical Research/Sir Charles Gairdner Hospital, Nedlands, Australia

Locations

  • United Kingdom

  • Switzerland

  • Australia

  • United States

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Gynaecological cancer

Biomarkers

  • N/A

Drug/Treatment

  • Afuresertib

  • Carboplatin

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Expansion Study

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT01653912

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved